Biodexa Pharmaceuticals (BDRX) Other Operating Expenses (2018 - 2021)

Biodexa Pharmaceuticals (BDRX) reported Other Operating Expenses of -$58358.4 for Q3 2021, down 247.32% sequentially from $39613.5 in Q4 2020.

Biodexa Pharmaceuticals (BDRX) Other Operating Expenses (2018 - 2021) Analysis & Trends

Biodexa Pharmaceuticals (BDRX) has 3 years of Other Operating Expenses data on file, last reported at -$58358.4 in Q3 2021.

For the quarter ending Q3 2021, Other Operating Expenses changed N/A year-over-year to -$58358.4; the trailing twelve-month figure through Sep 2022 stood at -$58358.4 (down 211.33% YoY), and the FY2020 full-year result was -$290217.0, changed N/A from the prior year.
Other Operating Expenses slipped to -$58358.4 in Q3 2021, from $39613.5 in the prior quarter.
In the past five years, Other Operating Expenses ranged from a high of $39613.5 in Q4 2020 to a low of -$1.8 million in Q4 2018.
A 3-year average of -$609742.1 and a median of -$58358.4 in 2021 frame the typical range for Other Operating Expenses.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Biodexa Pharmaceuticals	18.43 Bn	18.43 Bn	-

Download Data